Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 May;122(5):874-81.
doi: 10.1016/j.ophtha.2015.01.002. Epub 2015 Feb 9.

A randomized trial of levodopa as treatment for residual amblyopia in older children

Pediatric Eye Disease Investigator Group; Michael X Repka  1 , Raymond T Kraker  2 , Trevano W Dean  2 , Roy W Beck  2 , R Michael Siatkowski  3 , Jonathan M Holmes  4 , Cynthia L Beauchamp  5 , Richard P Golden  6 , Aaron M Miller  7 , Lisa C Verderber  8 , David K Wallace  9
Affiliations
Randomized Controlled Trial

A randomized trial of levodopa as treatment for residual amblyopia in older children

Pediatric Eye Disease Investigator Group et al. Ophthalmology. 2015 May.

Abstract

Objective: To assess the efficacy and short-term safety of levodopa as adjunctive treatment to patching for amblyopia.

Design: Randomized, placebo-controlled trial.

Participants: One hundred thirty-nine children 7 to 12 years of age with residual amblyopia resulting from strabismus, anisometropia, or both combined (visual acuity [VA], 20/50-20/400) after patching.

Methods: Sixteen weeks of oral levodopa or placebo administered 3 times daily while patching the fellow eye 2 hours daily.

Main outcome measures: Mean change in best-corrected amblyopic-eye VA at 18 weeks.

Results: At 18 weeks, amblyopic-eye VA improved from randomization by an average of 5.2 letters in the levodopa group and by 3.8 letters in the placebo group (difference adjusted for baseline VA, +1.4 letters; 1-sided P=0.06; 2-sided 95% confidence interval, -0.4 to 3.3 letters). No serious adverse effects from levodopa were reported during treatment.

Conclusions: For children 7 to 12 years of age with residual amblyopia after patching therapy, oral levodopa while continuing to patch 2 hours daily does not produce a clinically or statistically meaningful improvement in VA compared with placebo and patching.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No conflicting relationship exists for any author.

Figures

Figure 2
Figure 2. Change from Baseline in Amblyopic-Eye Visual Acuity by Treatment Group*
*The point estimates and standard errors for the mean change from baseline are shown. Not all participants continued randomized treatment after the 18-week visit.
See this image and copyright information in PMC

Comment in

References

    1. Pediatric Eye Disease Investigator Group. Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Arch Ophthalmol. 2005;123(4):437–47. - PubMed
    1. Pediatric Eye Disease Investigator Group. Two-year follow-up of a 6-month randomized trial of atropine vs patching for treatment of moderate amblyopia in children. Arch Ophthalmol. 2005;123(2):149–57. - PubMed
    1. Pediatric Eye Disease Investigator Group. Patching vs atropine to treat amblyopia in children aged 7 to 12 years: a randomized trial. Arch Ophthalmol. 2008;126(12):1634–42. - PMC - PubMed
    1. Leguire LE, Walson PD, Rogers GL, et al. Levodopa/carbidopa treatment for amblyopia in older children. J Pediatr Ophthalmol Strabismus. 1995;32(3):143–51. - PubMed
    1. Procianoy E, Fuchs FD, Procianoy L, Procianoy F. The effect of increasing doses of levodopa on children with strabismic amblyopia. J AAPOS. 1999;3(6):337–40. - PubMed

Publication types